New recommendations of the PRISMA 2020 version for systematic reviews and meta-analysis
Vol. 37 No. 2 (2021), Letter to the Editor
Vol. 37 No. 2 (2021)

New recommendations of the PRISMA 2020 version for systematic reviews and meta-analysis

Letter to the Editor
https://doi.org/10.22379/24224022373
Published 2021-07-07
Karen Vanessa Barrios Serna
Médico Interno, Corporación Universitaria Rafael Núñez, Cartagena de Indias, Colombia
Dannys Margarita Orozco Núñez
Médico Interno, Corporación Universitaria Rafael Núñez, Cartagena de Indias, Colombia
Erika Camila Pérez Navas
Médico Interno, Corporación Universitaria Rafael Núñez, Cartagena de Indias, Colombia
GianCarlos Conde Cardona
Neurólogo, grupo Ginumed, Corporación Universitaria Rafael Núñez, Cartagena de Indias, Colombia
https://doi.org/10.22379/24224022373

PDF (Español)
XML (Español)

References

Page M, McKenzie J, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol.2021;134:103-12. https://doi.org/10.1016/j.jclinepi.2021.02.003

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71

Bravo F. PRISMA 2020. Primum non nocere 2021. Blog [Internet]. Madrid [consulta 14 abril 2021]. Disponible en: Disponible en: https://rafabravo.blog/2020/09/20/prisma-2020/

Rondon E. ¿Es necesaria utilizar la declaración PRISMA en Ciencias de la Salud? Rev Cuba Enferme. 2020;36(4):e3582.

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https://doi.org/10.1136/bmj.n160

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Downloads

Download data is not yet available.